HomeCompareMKKGY vs JNJ

MKKGY vs JNJ: Dividend Comparison 2026

MKKGY yields 1.95% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MKKGY wins by $53.2K in total portfolio value
10 years
MKKGY
MKKGY
● Live price
1.95%
Share price
$25.60
Annual div
$0.50
5Y div CAGR
46.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$83.5K
Annual income
$26,382.95
Full MKKGY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — MKKGY vs JNJ

📍 MKKGY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMKKGYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MKKGY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MKKGY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MKKGY
Annual income on $10K today (after 15% tax)
$166.14/yr
After 10yr DRIP, annual income (after tax)
$22,425.51/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, MKKGY beats the other by $18,439.52/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MKKGY + JNJ for your $10,000?

MKKGY: 50%JNJ: 50%
100% JNJ50/50100% MKKGY
Portfolio after 10yr
$56.9K
Annual income
$15,536.18/yr
Blended yield
27.31%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

MKKGY
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
2.6
Piotroski
7/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MKKGY buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMKKGYJNJ
Forward yield1.95%2.13%
Annual dividend / share$0.50$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR46.8%28%
Portfolio after 10y$83.5K$30.3K
Annual income after 10y$26,382.95$4,689.40
Total dividends collected$58.0K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: MKKGY vs JNJ ($10,000, DRIP)

YearMKKGY PortfolioMKKGY Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$10,987$286.93$10,592$272.30+$395.00MKKGY
2$12,189$432.50$11,289$357.73+$900.00MKKGY
3$13,700$658.27$12,123$472.89+$1.6KMKKGY
4$15,674$1,015.12$13,141$629.86+$2.5KMKKGY
5$18,365$1,593.38$14,408$846.81+$4.0KMKKGY
6$22,211$2,561.31$16,021$1,151.60+$6.2KMKKGY
7$28,016$4,250.11$18,122$1,588.22+$9.9KMKKGY
8$37,332$7,354.91$20,930$2,228.20+$16.4KMKKGY
9$53,392$13,446.02$24,792$3,191.91+$28.6KMKKGY
10$83,512$26,382.95$30,274$4,689.40+$53.2KMKKGY

MKKGY vs JNJ: Complete Analysis 2026

MKKGYStock

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment also provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. The Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.

Full MKKGY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this MKKGY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MKKGY vs SCHDMKKGY vs JEPIMKKGY vs OMKKGY vs KOMKKGY vs MAINMKKGY vs ABBVMKKGY vs MRKMKKGY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.